Az n-3 többszörösen telítetlen zsírsavak enteralis adása akut pancreatitisben - Elozetes eredmények

Translated title of the contribution: Enteral administration of n-3 polyunsaturated fatty acids in acute pancreatitis

Natália Lásztity, József Hamvas, Lajos Bíró, Éva Németh, Tamás Marosvölgyi, Tamás Decsi, Ákos Pap, Magda Antal

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND - The main determinant of outcome in acute pancreatitis is the extent of inflammation and pancreatic necrosis. Early administration of n-3 polyunsaturated fatty acids (PUFAs) may prevent the development of severe complications through modulation of eicosanoid synthesis and cytokine release. PATIENTS AND METHODS - In the prospective, randomised clinical trial 14 patients with acute pancreatitis received n-3 PUFAs (3.3 g/day for 5-7 days) as a supplement to their enteral formula in the form of fish oil, and another 14 patients receiving enteral nutrition served as a control group. Measurements of erythrocyte superoxide-dysmutase activity, serum total antioxidant status, C-reactive protein and praealbumin concentrations were performed at admission and at day 3, 7 and 14. Beside routine laboratory and imaging examinations, the fatty acid and vitamin A and E concentrations of the serum lipid fractions were also determined at admission and at day 7 of the jejunal nutrition. The endpoints of the study were the duration of hospitalisation, the duration of jejunal nutrition and the frequency of complications. RESULTS - A significantly higher superoxide-dysmutase activity was observed in patients receiving n-3 fatty acids at day 3 of the treatment. The n-3 to n-6 long chain PUFA ratio increased significantly in the serum lipids of the patients receiving n-3 PUFA supplementation, whereas remained unchanged in the controls. Supplementation resulted in a significant decrease in the length of hospitalisation (13.1±6.7 vs. 19.3±7.2 days, p<0.05) and jejunal feeding (10.6±6.7 vs. 17.6±10.5, p<0.05). Complications developed in 6/14 (42%) of the treated group and in 9/14 (64%) of the control patients. CONCLUSION - Enteral administration of n-3 PUFAs in acute pancreatitis may promote earlier recovery by moderating inflammation.

Original languageHungarian
Pages (from-to)848-854
Number of pages7
JournalLege Artis Medicinae
Volume16
Issue number10
Publication statusPublished - Oct 1 2006

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this